A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Male Subjects With High Serum Uric Acid Level
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
Price : $35 *
At a glance
- Drugs SHR 4640 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors Atridia
- 31 Aug 2018 Biomarkers information updated
- 20 Mar 2018 Status changed from recruiting to completed.
- 15 Oct 2017 Status changed from not yet recruiting to recruiting.